Russians rushed to buy Botox
From January to October 2023, sales of cosmetic products reached 960.5 thousand packages. In the same period of 2021, sales volumes amounted to 307.6 thousand units. In monetary terms, sales doubled, from 1.7 to 3.4 billion rubles. The volume of the botulinum toxin-based drugs market has grown against the background of the statement by the American pharmaceutical company Abbvie about the termination of supplies to Russia due to the fighting in Ukraine. For example, sales of the Botox analogue, Relatox, produced by the Moscow research and production association Microgen, increased by 185 percent.
According to Alexander Terentyev, director of the National Association of Aesthetic Medicine Clinics (NACEM), the increase in drug sales is due to the spread of illegal cosmetic services. Now their share reaches 40 percent of the market, which is estimated at 100 billion rubles. At the same time, the use of botulinum toxins is a "purely medical procedure" that requires professional medical knowledge, compliance with the techniques of administration and dosages of the drug, the expert added.
After the Russian Ministry of Health decided in October to tighten the sale of abortion drugs such as mifepristone and misoprostol, Russians began buying drugs for unwanted pregnancies.